| Project/Area Number |
25462502
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Tokyo Medical University |
|---|
Principal Investigator |
NAKASHIMA Jun 東京医科大学, 医学部, 教授 (10167546)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TACHIBANA Masaaki 東京医科大学, 医学部, 教授 (70129526)
OHNO Yoshio 東京医科大学, 医学部, 准教授 (40266482)
HORIGUCHI Yutaka 東京医科大学, 医学部, 准教授 (60229234)
HASHIMOTO TAKESHI 東京医科大学, 医学部, 助教 (10421033)
GONDO Tatsuo 東京医科大学, 医学部, 講師 (90408097)
HIRASAWA Yosuke 東京医科大学, 医学部, 助教 (10725310)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | urological cancers / NFkappaB / cytotoxicity / inflammation / prognosis / 泌尿器系癌 / 抗腫瘍効果 / 炎症反応 / 炎症 |
|---|
| Outline of Final Research Achievements |
Novel NFκB inhibitors showed significant cytotoxicity on our cell lines derived from bladder cancer (BC), renal cell cancer (RCC) and prostate cancer (PC). Although some compounds failed to show a significant induction of apoptosis in PC cells, newly developed compounds showed significant cytotoxic effects on DU145 and PC3 cells. The expression of legumain was confirmed at the mRNA and protein levels in our PC cell lines. The immunochemical-staining patterns of legumain in prostatectomy specimens were significantly associated with unfavorable pathology and prognosis. However, hypoxia and so on did not regulate the expression of legumain. Sarcopenia, NLR and CRP were significantly associated with prognosis in patients with invasive BC, CRPC and advanced RCC and pyuria was an independent prognostic factor for intravesical recurrence in patients with superficial BC, which suggest that inflammatory immune response may play a key role in the disease progression in urological malignancies.
|
